Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
21.36
-0.82 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Recap: Bicycle Therapeutics Q3 Earnings
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Expert Ratings for Bicycle Therapeutics
August 22, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Bicycle Therapeutics
May 23, 2022
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
May 06, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
May 05, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
August 31, 2022
Upgrades
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
August 22, 2022
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83...
Via
Benzinga
Bicycle Therapeutics: Q2 Earnings Insights
August 04, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Where Bicycle Therapeutics Stands With Analysts
July 06, 2022
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 24, 2022
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press...
Via
Benzinga
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
June 08, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
June 06, 2022
Monday's session saw 84 companies set new 52-week lows.
Via
Benzinga
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
Bicycle Therapeutics
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
May 27, 2022
Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter.
Via
Benzinga
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
May 26, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.